REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Enid News & Eagle20d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value ...
SAN FRANCISCO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...
FiercePharma1d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Morningstar27d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron's statements about its compliance with applicable rules and regulations ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
WATE 6 On Your Side7d
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman
SAN FRANCISCO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...
Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...
Mena FN8d
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors With Substantial Losses Have Opportunity To Lead Investor Class Action Lawsuit
Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and certain of Regeneron's top current and former executives ...